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Research
The use of engineered nanoparticles (NPs) 
has increased significantly in the past decade. 
Because of the flexibility of producing NPs 
of different sizes, shapes, and surface modi-
fications, engineered NPs can be used in a 
variety of applications, including skin care 
products, foods, electronics, and medi  cine. 
Anthropogenic sources of NPs also emerge 
from power plants and industries. It is likely 
that humans will be exposed to NPs through 
dermal absorption, ingestion, and inhalation. 
This may pose a health concern because stud-
ies have shown that NPs can elicit adverse 
cellu  lar effects in vitro (Fubini and Hubbard 
2003; Napierska et al. 2009; Park and 
Park 2009). A recent study has shown that 
workers occupationally exposed to NPs for 
5–13 months exhibited symptoms of pulmo-
nary fibrosis, with NPs present in the cyto-
plasm of pulmonary epithelial and mesothelial 
cells (Song et al. 2009).
Entry of engineered NPs into the brain 
may be possible via several pathways. One of 
the well-studied pathways is the nose-to-brain 
transport through the olfactory epithelium. 
Olfactory sensory neurons (OSNs) reside in 
the olfactory epithelium and have processes in 
direct contact with the outside environment. 
Thus, NPs might be able to gain access to the 
brain by OSNs and its projections to the olfac-
tory bulb and subsequently to other regions in 
the brain (Calderón-Garcidueñas et al. 2002; 
Oberdörster et al. 2004). Another possible 
nose-to-brain transport can occur through the 
tri  geminal nerve, the largest of the cranial 
nerves. Afferent neurons from the tri  geminal 
nerve pass directly through the nasal mucosa 
and enter the brainstem at the level of the pons 
(Mistry et al. 2009). For example, in rats, intra-
nasal adminis  tra  tion of the neuro  trophic factor 
insulin-like growth factor-1 (IGF-1) resulted 
in the delivery of IGF-1 to both the olfactory 
bulb and brainstem areas (Thorne et al. 2004). 
In addition, NPs can be synthetically engi-
neered to bypass the blood–brain barrier. One 
of the cardinal features of the blood–brain bar-
rier is the tight junction that is formed between 
endothelial cells, restricting the passage of 
xeno  biotics into the central nervous system 
(CNS). However, depending on their size and 
chemical composition, engineered NPs may 
bypass the BBB and gain direct entry into the 
brain (Lockman et al. 2004).
In the brain, microglia are immuno-
competent cells and represent approximately 
5–10% of the glial cell population. As the sen-
tinels of the CNS, microglia are the first cells to 
respond to disruption of brain homeo  stasis and 
entry of foreign particles or infectious agents. 
Once activated, microglia can undergo mor-
phological and functional changes, including 
proliferation, migration to the site of injury, 
and phago  cytosis of cellular debris. Activated 
microglia can also generate reactive oxygen 
species (ROS) and reactive nitrogen species 
(RNS) and elicit an inflammatory response 
(Streit et al. 1999, 2005; Tambuyzer et al. 
2009). Thus, microglia are the brain cells 
most likely to respond to the entry of NPs, 
and several studies have suggested this pos-
sibility (Kircher et al. 2003; Ribot et al. 2007; 
Voisin et al. 2007). Engineered NPs have 
been shown to trigger oxidative stress in vitro; 
because the brain is highly vulnerable to oxi-
dative stress, increased ROS production can 
lead to neuro  degeneration (Block et al. 2007; 
Long et al. 2007). One study showed that 
nano  size titanium dioxide, commonly used 
in skincare products, stimulates the produc-
tion of ROS in immortalized brain microglia 
and damages neurons in vitro (Long et al. 
2007). Other studies suggest the plausible role 
of ultra  fine particles found in air pollution in 
neuro  inflammation and in the induction of 
pathology associated with Alzheimer’s disease 
(Calderón-Garcidueñas et al. 2002, 2004).
Silica is a major component of sand and 
glass, and it has been used in the synthesis of 
NPs. Silica NPs (SiNPs) are generally deemed 
non  toxic and are inexpensive and easy to pro-
duce. Functional groups can also be added to 
the surface, making them appealing for designs 
for different applications (Roy et al. 2005; 
Wang et al. 2008). SiNPs are being formulated 
for potential drug delivery and for imaging and 
diagnostic applications in the CNS because 
they are considered to be more bio  compatible 
than are other imaging NPs, such as quantum 
dots, which may contain toxic metals such as 
cadmium and mercury (Bharali et al. 2005; 
Liu et al. 2008; Manzoor et al. 2009; Roy et al. 
2005; Su et al. 2009). Studies have proposed 
microglia as a vehicle for the delivery of NPs 
to tumors for imaging or drug delivery (Ribot 
et al. 2007; Voisin et al. 2007).
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Ba c k g r o u n d: Silica nanoparticles (SiNPs) are being formulated for cellular imaging and for non-
viral gene delivery in the central nervous system (CNS), but it is unclear what potential effects 
SiNPs can elicit once they enter the CNS. As the resident macrophages of the CNS, microglia are 
the cells most likely to respond to SiNP entry into the brain. Upon activation, they are capable of 
undergoing morphological and functional changes.
oB j e c t i v e: We examined the effects of SiNP exposure using primary rat microglia. 
Me t h o d s : We observed microglial uptake of SiNPs using transmission electron and fluorescence 
confocal microscopy. Microglial functions, including phagocytosis, generation of reactive oxygen spe-
cies (ROS) and reactive nitrogen species (RNS), expression of pro  inflammatory genes, and cytokine 
release, were measured after SiNP exposure at different concentrations.
re s u l t s: Microglia are capable of avidly taking up SiNPs at all concentrations tested. These same 
concentrations did not elicit cytotoxicity or a change in phagocytic activity. SiNPs did increase the 
productions of both intracellular ROS and RNS. We also observed a significant decrease in tumor 
necrosis factor-α gene expression at all concentrations tested and a significant increase in COX-2 
(cyclooxygenase-2) gene expression at the highest concentration of SiNPs. Analysis of cytokine 
release showed a detectable level of interleukin-1β.
co n c l u s i o n s: This is the first study demonstrating the in vitro effects of SiNPs in primary micro-
glia. Our findings suggest that very low levels of SiNPs are capable of altering microglial function. 
Increased ROS and RNS production, changes in pro  inflammatory genes, and cytokine release may 
not only adversely affect microglial function but also affect surrounding neurons.
key w o r d s : inflammation, microglia, nanoparticle, neurotoxicity, ROS, RNS, silica. Environ 
Health Perspect 118:589–595 (2010).  doi:10.1289/ehp.0901534 [Online 21 December 2009]Choi et al.
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We synthesized the SiNPs used in this 
study using the Stöber method, which is 
known to generate amorphous SiNPs of a 
controlled size (Stöber et al. 1968). In addi-
tion, the SiNPs were embedded with a fluo-
rescent dansyl  amide dye, allowing them to be 
tracked in cells. The physico  chemical proper-
ties of these particular SiNPs have been pre-
viously charac  terized (Nyland et al. 2009). 
Incorporation of dansylamide dye molecules 
inside the silica matrix protects the dye from 
the surrounding environment and provides 
signal enhancement due to an increase in the 
number of dye molecules per NP without dye 
aggregations (Ow et al. 2005; Sokolov and 
Naik 2008). Energy-dispersive X-ray spectros-
copy showed that these dansylamide-embedded 
SiNPs are not contaminated with other metals 
(Nyland et al. 2009). Another primary concern 
of testing the toxicity of NPs is the concept of 
NP aggregation, which can result in mis  leading 
information. Thus, we tested these SiNPs for 
stability and for clumping in cell culture media 
using scanning electron microscopy (SEM) and 
dynamic light scattering. These SiNPs were 
stable in cell culture media for approximately 
1 week, and no clumping or aggregation was 
observed (Nyland et al. 2009; Thomassen et al. 
2010). The goal of the present study was to 
determine whether these fluorescent SiNPs 
can be taken up by primary microglia from rat 
brain and to determine whether they disrupt 
microglial function.
Materials and Methods
Synthesis and characterization of SiNPs. The 
NPs used in this study were formed in an emul-
sion where 0.5 g of the hydrophobic phase, 
high-molecular-weight poly(dimethylsiloxane) 
(Scientific Polymer Products, Ontario, NY), 
was dissolved in 2 mL of the sol-gel precursor 
tetraethyl orthosilicate (Aldrich, Milwaukee, 
WI) and 70 mL ethanol (Aldrich), the hydro-
philic phase. Then 0.05 g dansyl-amino  propyl-
triethoxysilane (dansylamide dye; Gelest, 
Morrisville, PA) was added to the solution and 
ultimately became covalently bonded to the 
cross-linked silica network. Control experi-
ments established that this networking was 
essential for retention of the dye inside the par-
ticles. After adding 10 mL ammonium hydrox-
ide (NH4OH) to initiate the polymerization 
process, 0.4 g Dow 190 surfactant (silicone 
ethylene oxide/propylene oxide copolymer; 
Dow Corning, Midland, MI) was added. The 
reaction was allowed to continue for 12 hr at 
room temperature. After the reaction was com-
pleted, NPs were washed with ethanol and 
deionized water to remove surfactant and then 
centrifuged five times. The NPs were finally 
resuspended in 100% ethanol. The final par-
ticle concentration was determined by averag-
ing the number of counts in the field of view in 
20 SEM images of a mono  layer of 3.5 mg/mL 
NPs. The size, shape, and concentration of 
NPs (expressed as NPs per milli  liter ethanol) 
were examined under SEM (JEOL 6700F) 
and an energy-dispersive X-ray spectroscopy 
microanalysis system (JEOL USA, Peabody, 
MA). Fluorescence of the dye-doped NPs 
was measured with a Hitachi F-4500 spectro-
photometer (Hitachi, Schaumberg, IL). The 
fluorescence emission of the dansylamide-
doped NPs was at 460–480 nm, a wavelength 
detectable using fluorescence microscopy.
The dansylamide-embedded SiNPs were 
also characterized before treatment. Figure 1A 
is an SEM image of the dansylamide-em-
bedded SiNPs suspended in culture media. 
The NPs are spherical in shape and about 
150–200 nm in diameter. These SiNPs do 
not aggregate in cell culture media, and the 
dansylamide dye mole  cules do not leak out 
as they are incorporated into the NP matrix. 
The size distribution and the surface charge 
of these SiNPs were measured by photon 
correlation spectroscopy using a Zetasizers 
3000 (Malvern Instruments, Southborough, 
MA). The size distribution of these SiNPs 
(Figure 1B) indicates the absence of aggre-
gation. The overall surface charge of these 
SiNPs, determined by their zeta-potential val-
ues, is negative (–23 mV; Figure 1C) because 
of the hydroxyl groups on their surface. 
Primary microglia cell culture. Primary 
mixed glial cell cultures were prepared using a 
modified version of the glial culture technique 
as previously described (Giulian and Baker 
1986). Briefly, 9–10 brains from post  natal 
day 1–3 Sprague-Dawley rat pups (Harlan, 
Indianapolis, IN) were dissected, and the 
meninges were carefully removed. Brain tissue 
was dissociated by trypsination (0.25% trypsin 
at 37°C for 30 min), trituration, and filtration 
through 40-µm cell strainers. Cells were cen-
trifuged at 2,000 × g for 10 min, resuspended, 
and plated onto 75-cm2 poly-l-lysine–coated 
culture flasks in Dulbecco’s modified Eagle 
medium (DMEM)/F12 (Invitrogen, Carlsbad, 
CA) containing 10% heat-inactivated fetal 
bovine serum (FBS; Hyclone, Logan, UT), 
and 100 U penicillin/100 µg streptomycin 
(Invitrogen). Cultures were maintained at 
37°C in a humidified chamber of 95% air/5% 
CO2 for 12–14 days, when the glial cultures 
reached confluency. Microglia were then 
separated from the glial cultures by shaking 
the flasks for 2 hr at 200 rpm at 37°C and 
collected as floating cells in the media. After 
centrifugation (2,000 × g for 10 min), cell 
viability was determined by trypan blue exclu-
sion, and cells were plated on 96-well plates, 
6-well plates, or 60-mm dishes, depending on 
the assay being tested. Non  adherent cells were 
removed 20 min after plating by changing 
the culture medium to DMEM/F12 contain-
ing 2% FBS. Adherent cells were incubated 
overnight before being used for experiments. 
More than 95% of the adherent cells were 
positive for microglia-specific marker Mac-1 
(Chemicon, Billerica, MA) as determined by 
immuno  staining. Figure 2 shows an image 
of primary microglia in culture prior to treat-
ment. The animals used for this study were 
treated humanely and with regard for allevia-
tion of suffering. All the animal studies were 
reviewed and approved by the Johns Hopkins 
University Animal Care and Use Committee.
Experimental conditions for SiNP treat-
ments. We used a series of SiNP concentra-
tions to test possible effects on primary 
microglia. The SiNP stock solution (con-
centrations ranging from 4 × 1010 NPs/mL 
to 7 × 1010 NPs/mL) was diluted in 100% 
Figure 1. The physicochemical properties of the dansylamide-embedded SiNPs. (A) SEM image of the 
SiNPs (diameters range from approximately 150 to 200 nm; magnification, 19,000x). Dynamic light scattering 
data showing the size distribution by volume (~ 180 nm, polydispersity index = 0.038; B) and zeta potential 
distribution (–23 mV; C) of SiNPs. 
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ethanol to the appropriate concentrations 
(shown in Table 1), and the NPs were added 
to DMEM/F12 medium containing 2% FBS; 
ethanol content in the solutions was < 1%. 
Microglia were exposed to SiNPs for 24 hr 
before being assayed. In some experiments, 
bacterial lipo  poly  saccharide (LPS; Sigma-
Aldrich, St. Louis, MO) was used as a positive 
control to assess microglial function. Table 1 
shows the conversions of the NPs/volume con-
centrations used in this study to mass/volume. 
The concentrations we used were similar to or 
less than the concentrations used in previously 
published in vivo NP studies (He et al. 2008; 
Lockman et al. 2004).
Cell viability. Cell viability was determined 
using Promega CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay {MTS 
[3-(4, 5-dimethylthiazol-2-yl)-5-(3 carboxy-
methoxy  phenyl)-2-( 4-sulfophenyl)-2H-tetra-
zolium, inner salt]; Promega, Madison, WI} 
according to the manufacturer’s instructions. 
Briefly, 30,000 microglia/well were plated onto 
96-well plates. Four hours before the end of 
the exposure, MTS was added, and at the end 
of exposure, the plate was read at 490 nm.
Measurement of ROS. We measured ROS 
using the 2´,7´-dichlorohydrofluorescein diac-
etate (H2DCFDA) assay (Molecular Probes, 
Eugene, OR). Nonfluorescent H2DCFDA 
readily crosses the cell membranes and gets 
deacetylated to H2DCF by intracellular 
esterases. After oxidation by ROS, H2DCF 
is converted to the highly fluorescent DCF, 
which is detectable using a fluorescent plate 
reader. A 2.5-mM stock solution of DCF-DA 
was first made in dimethyl sulfoxide (DMSO; 
Sigma-Aldrich) and then diluted in Hank’s 
balanced salt solution (HBSS) so that the 
percentage DMSO in solution was < 1%. A 
total of 30,000 microglia/well was plated onto 
a 96-well plate. After 24-hr exposure, cul-
ture medium was removed and the cells were 
washed in HBSS. Cells were incubated for 
30 min at 37°C in HBSS containing 10 µM 
DCF-DA. After incubation, medium was 
aspirated and the cells were washed twice with 
HBSS. The plate was read at 485 nm excita-
tion and 530 nm emission.
Measurement of RNS. We measured 
RNS using the 4-amino-5-methylamino-
2´,7´-difluoro  fluorescein (DAF-FM) assay 
(Invitrogen). DAF-FM readily crosses the cell 
membranes and is deacetylated by intra  cellular 
esterases to 4,5-diaminofluorescein (DAF-2). 
DAF-2 remains essentially non  fluorescent 
until it reacts with the nitrosonium cation 
(produced by spontaneous oxidation of nitric 
oxide) to form a fluorescent benzo  triazole, 
which is detectable using a fluorescent plate 
reader. A 5-mM stock of DAF-FM was first 
made in DMSO and then diluted in HBSS 
so that the percentage DMSO in solution 
was < 1%. We plated 30,000 microglia/well 
onto a 96-well plate. After 24-hr exposure, 
culture medium was removed and the cells 
were washed in HBSS. Cells were incubated 
for 30 min at 37°C in HBSS containing 1 µM 
DAF-FM. After incubation, medium was aspi-
rated and the cells were washed twice with 
HBSS. The plate was read at 495 nm excita-
tion and 515 nm emission.
Phagocytosis. We measured microglial 
phagocytosis using fluorescent poly  styrene 
micro  beads (1 µm diameter; Molecular 
Probes). The emission wavelength for these 
beads is 598 nm, which does not overlap 
with the fluorescence of the SiNPs. A stock 
solution of 1 × 1010 beads/mL was diluted in 
HBSS to generate a solution of 50–100 fluo-
rescent poly  styrene beads per cell. We then 
plated 30,000 microglia/well onto a 96-well 
plate. After 24-hr exposure, medium was aspi-
rated, and cells were washed and incubated for 
30 min at 37°C in HBSS containing the fluo-
rescent poly  styrene beads. After incubation 
and washing, the plate was read at 570 nm 
excitation and 598 nm emission.
SiNP uptake using fluorescence confo-
cal microscopy and transmission electron 
microscopy (TEM). We plated 250,000 pri-
mary microglia/well onto 6-well plates with 
a glass coverslip per well. After 24-hr expo-
sure, microglial cells were fixed with 4% 
paraformaldehyde (15 min at room tem-
perature) followed by 0.2% Triton (10 min 
at room temperature). The cells were then 
blocked in phosphate-buffered saline (PBS) 
containing 10% normal goat serum for 1 hr 
at room temperature before being incubated 
with mouse anti-Mac-1 primary antibody 
(1:100; Chemicon) overnight at 4°C. After 
three washes in PBS, the cells were incubated 
with goat anti-mouse Alexa 594 secondary 
anti  body (1:500; Invitrogen). After three 
final washes in PBS, the cells were mounted 
with Prolong with DAPI (4,6-diamidino-2-
phenyl  indole; Invitrogen) to counter  stain for 
the nuclei. Fluorescence confocal images were 
taken using Zeiss LSM510-Meta (Carl Zeiss 
Microimaging Inc., Thornwood, NY) at the 
Johns Hopkins University (JHU) School of 
Medicine Microscope Facility. 
For TEM, we plated 250,000 primary 
microglia/well per treatment onto 35-mm 
dishes. After 24-hr exposure, cells were 
washed and fixed in 2% glutaldehyde. The 
samples were then sent to the JHU School 
of Medicine Microscope Facility for electron 
microscopy preparation. TEM images were 
taken using a Hitachi 7600 TEM. 
Cytokine production profiling using 
Luminex (Luminex Corp., Austin, TX). For 
profiling of cytokine production, we plated 
30,000 primary microglia/well onto a 96-well 
plate. After 24-hr exposure, 50 µL of the 
culture medium was collected to be assayed 
for 10 different cytokines [granulocyte/
macrophage colony–stimulating factor, 
interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-6, 
IL-10, IL-12, interferon-γ, and tumor necro-
sis factor (TNF-α)] using the Cytokine Rat 
10-Plex Panel (Invitrogen) according to the 
manufacturer’s instructions. 
Changes in gene expression using quan-
titative real-time polymerase chain reaction 
(qRT-PCR). We plated 500,000 primary 
microglia per treatment onto 60-mm dishes. 
After 24-hr exposure, total RNA was isolated 
from each plate using the Qiagen RNeasy 
Mini Kit (Qiagen, Valencia, CA) accord-
ing to the manufacturer’s instructions. The 
quality of RNA was tested using an Agilent 
Bioanalyzer (Quantum Analytics, Inc., Foster 
City, CA). We used 50 ng total RNA for 
reverse transcription using the Sensiscript RT 
Kit (Qiagen) according to manufacturer’s 
instructions. The final cDNA product was 
diluted to a final volume of 100 µL, and 5 µL 
of cDNA per gene of interest was used for 
qRT-PCR, which was performed using the 
Applied Biosystems Real-Time PCR 7000 
Sequence Detection System with Taqman 
Universal PCR Master Mix and rat TNF-α 
[GenBank accession no. NM_012675.2 
(http://www.ncbi.nlm.nih.gov/Genbank/)] 
and rat cyclo  oxygenase-2 (COX‑2; GenBank 
accession no. NM_017232.3) Taqman prim-
ers (all from Applied Biosystems, Foster City, 
CA). β-Actin was used as the internal control 
for these experiments. qRT-PCR analysis was 
performed using the ΔΔCt method.
Figure 2. Light microscopy of primary rat microglia 
in culture. Primary rat microglia were extracted 
from mixed glial cultures and plated for 16–20 hr 
before use. Microglia appear healthy, with pro-
cesses and a ramified morphology. 
100 µm
Table 1. Conversion of concentrations used (nano-
particles/volume) to mass/volume.
NPs/µL Mass/volume (µg/mL)
1.2 2.18 × 10–4
4 7.28 × 10–4
20 3.64 × 10–3
120 0.0218
400 0.0728
2,000 0.364
12,000 2.18
40,000 7.28
200,000 36.4Choi et al.
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Statistical analysis. Values are expressed as 
mean ± SE. Each group consisted of three or 
four independent trials for each concentration 
studied. We used a one-way analysis of vari-
ance to determine treatment effect followed 
by Fisher’s post hoc analysis.
Results
Uptake of SiNP by primary microglia. We 
exposed primary microglia to various concen-
trations of SiNPs for 24 hr. Confocal fluores-
cent microscopy showed the internalization 
of SiNPs by microglia at all concentrations 
tested (Figure 3). At the highest concentration, 
40,000 NPs/µL (equivalent to 7.28 µg/mL), 
nearly every microglia showed uptake of SiNPs. 
At this concentration, primary microglia looked 
hyper  trophic compared with lower concentra-
tions (Figure 3C). We also detected uptake 
of SiNPs by TEM. At 4 NPs/µL (7.28 × 10–4 
µg/mL), SiNPs were present within the cyto-
plasm but did not appear to accumulate in 
phagocytic vacuoles (Figures 4B, 5B). In con-
trast, at 400 NPs/µL (7.28 × 10–2 µg/mL; 
Figures 4C, 5C) and 40,000 NPs/µL (7.28 µg/
mL; Figures 4D, 5D), SiNPs were present 
in what appear to be phagocytic vacuoles. 
Analysis of the diameter of SiNPs in the cyto-
plasm and in phagocytic vacuoles of microglia 
(Figure 5B–D) is consistent with the known 
distribution of the diameter for most of the 
SiNPs, which is approximately 150–200 nm 
(Figure 1B).
Cell viability and phagocytosis. We exam-
ined whether SiNPs are cytotoxic to micro-
glia, by measuring cell viability using the 
MTS assay. We used LPS, a potent inflam-
magen, as a positive control because it is a 
well-known activator of microglia (Facchinetti 
et al. 2003; Minghetti and Levi 1995). After 
a 24-hr exposure to SiNPs, we observed no 
significant difference in cell viability at any 
of the SiNP concentrations tested relative 
to the vehicle control (Figure 6). However, 
LPS generated a positive response compared 
with vehicle and all the SiNP concentrations 
tested (F7,19 = 32.67; p = 0.0001), which may 
be related to an effect of LPS on microglial   
proliferation. 
To determine whether SiNPs can alter 
phagocytic activity, we exposed primary 
microglia to SiNPs for 24 hr before the addi-
tion of fluorescent poly  styrene micro  spheres, 
which are commonly used to assess phagocytic 
Figure 3. Uptake of SiNPs by primary microglia detected by fluorescence confocal microscopy, showing intra  cellular accumulation of SiNPs at three concentra-
tions tested: 4 NPs/µL (A), 400 NPs/µL (B), and 40,000 NPs/µL (C). Arrows indicate cells that have accumulated SiNPs. It appears that microglia became hyper-
trophic with increased SiNP concentrations, based on the expansion of their cytoplasm. SiNPs are shown in green; Mac-1 (red) is a microglia-specific marker, 
and DAPI (blue) is a nuclei-specific marker. 
10 µm 10 µm 10 µm
Figure 4. Uptake of SiNPs by primary microglia revealed by TEM. (A) Image of a normal microglia (magnifi-
cation, 5,000x). (B) Microglia exposed to 4 NPs/µL; SiNPs were dispersed throughout the cytoplasm (mag-
nification, 5,000x). (C) Microglia exposed to 400 NPs/µL; there was uptake of SiNPs into what it appears to 
be phagocytic vacuoles (arrow; magnification, 8,000x). (D) Microglia exposed to the highest concentration 
tested (40,000 NPs/µL); numerous phagocytic vacuoles contained SiNPs (magnification, 6,000x). 
2 µm
2 µm 2 µm
2 µmMicroglial response to nanoparticles
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activity. The microspheres are detected at a 
different wavelength (emission at 598 nm) 
than the SiNPs (emission at 460–480 nm), so 
SiNP fluorescence does not interfere with this 
phagocytic activity assay. Figure 7 shows that 
SiNPs did not produce a significant effect on 
microglial phagocytic activity (F3,8 = 0.775; 
p = 0.540). We also tested phago  cytosis at 
an earlier time point of SiNP exposure (i.e., 
30 min), and did not observe a difference in 
phagocytic activity (data not shown). In sum-
mary, SiNPs at the concentrations tested were 
not cytotoxic to primary microglia, nor did 
they alter phagocytosis.
Production of ROS and RNS. Although 
cell viability was not altered by SiNPs, we 
were interested in determining whether SiNPs 
could induce the production of intra  cellular 
ROS and RNS. It is known that, upon acti-
vation, microglia are capable of generating 
both ROS and RNS. After 24 hr exposure 
to SiNPs, we observed a consistent and sig-
nificant increase in intra  cellular production of 
ROS (F4,11 = 8.47; p = 0.0023; Figure 8A) and 
RNS (F4,11 = 9.85; p = 0.0012; Figure 8B). 
These increased levels of intra  cellular ROS 
and RNS were present even at the lowest con-
centration tested, and were similar to the level 
produced by 100 ng/mL LPS (Figure 8). 
Gene expression of pro  inflammatory mark-
ers. To determine if exposure to SiNPs can 
induce an inflammatory response in primary 
microglia, we measured the levels of the pro-
inflammatory genes TNF‑α and COX‑2 
using qRT-PCR. After 24 hr of SiNP expo-
sure, we observed a significant decrease in 
TNF‑α gene expression at all concentrations 
tested (F4,12 = 79.27; p = 0.0001) and a sig-
nificant increase in COX‑2 gene expression at 
the highest concentration of 200,000 NPs/
µL (36.4 µg/mL of SiNPs; (F4,10 = 43.30; 
p = 0.0001) (Figure 9). 
Cytokine release. We examined the effect 
of SiNPs on the release of inflammatory cyto-
kines, using Luminex technology, which can 
simultaneously measure 10 different cyto-
kines. Under the conditions used, we meas-
ured low but detectable levels of IL-1β after 
SiNP exposure. In contrast, IL-1β was not 
detectable in the culture medium from vehi-
cle-exposed microglia. Microglia treated with 
100 ng/mL LPS served as a positive control, 
and this treatment resulted in a robust increase 
in IL-1β release (Figure 10).
Discussion
In this article we provide in vitro evidence 
for the effects of SiNPs on primary microglia 
from rat brain. Using both TEM and fluo-
rescence confocal microscopy, we found that 
primary microglia can take up SiNPs when 
exposed to very low concentrations (as low as 
4 NPs/µL, or 7.28 × 10–4 µg/mL). Although 
these SiNPs do not exert acute cyto  toxicity 
at the concentrations tested or alter phago-
cytic activity of microglia, SiNPs did increase 
intra  cellular ROS and RNS levels. Previous 
studies have shown that intra  cellular ROS 
acts as a signal that stimulates the produc-
tion of inflammatory markers (Pei et al. 2007; 
Wang et al. 2004). This is consistent with our 
observation that microglia exposed to SiNPs 
released detectable levels of IL-1β. We also 
observed a consistent decrease in TNF‑α gene 
expression at all SiNP concentrations and a 
significant increase in COX‑2 gene expres-
sion at the highest concentration. We do not 
yet understand the reason for the decrease in 
TNF‑α gene expression. A change in COX-2 
Figure 5. TEM images showing the diameters of the SiNPs inside the microglia. (A) Normal microglia with no 
SiNPs (magnification, 12,000x). (B–D) Higher-magnification TEM images of microglia exposed to 4 NPs/µL (B; 
magnification, 12,000x), 400 NPs/µL (C; magnification, 30,000x), and 40,000 NPs/µL (D; magnification, 25,000x). 
Diameters of SiNPs inside the microglia ranged from 131 nm to 197 nm. 
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Figure 6. Effects of SiNPs on microglial cell viability. 
Data are normalized to vehicle and expressed as 
mean ± SE of three independent trials. 
#p < 0.05 compared with all treatments.
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Figure 7. Effects of SiNPs on microglial phagocy-
tosis, determined using fluorescent poly  styrene 
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Data are normalized to vehicle and expressed as 
mean ± SE of three independent trials. 
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activity may be involved. Previous studies 
have shown that enhanced COX-2 activity 
and subsequent increase in prostaglandins 
such as PGE2 (prosta  glandin E2) has a nega-
tive feedback in TNF-α (Aloisi et al. 1999; 
Levi et al. 1998; Zhang and Rivest 2001). 
PGE2 might exert this effect by increasing 
the level of intra  cellular cAMP because the 
effect of PGE2 on down-regulating TNF-α 
was mimicked by cAMP-elevating agents 
(Minghetti et al. 1997). However, this is only 
speculative, and future studies are needed to 
examine this possibility.
An interesting observation from this study 
is that at the lowest concentration (4 NPs/µL; 
7.28 × 10–4 µg/mL), the SiNPs did not appear 
to be localized in phagocytic vacuoles but were 
dispersed throughout the cytoplasm. In con-
trast, at higher concentrations, SiNPs appeared 
to be engulfed in phagocytic vacuoles. This 
suggests different mechanisms of SiNP uptake 
based on SiNP concentration. Future studies 
will examine the effects of concentration, size, 
and surface modification of SiNPs on primary 
microglial uptake and function, because smaller 
SiNPs with a higher surface area can elicit a 
greater dose-dependent cytotoxicity than larger 
NPs (Lin et al. 2006; Napierska et al. 2009; 
Shvedova et al. 2007).
This study provides important insights on 
possible adverse effects on primary microglia 
exposed to SiNPs in vitro. The results can 
guide experimental animal studies in which 
SiNPs are administered in vivo. This is an 
important next step because reports have 
demonstrated the use of SiNPs for drug deliv-
ery into the CNS without assessing poten-
tial toxic effects. Our present results showed 
the effects of only 24-hr exposures to SiNPs. 
However, if SiNPs are not readily degrad-
able or eliminated from the CNS, then it is 
probable that SiNPs would accumulate in 
the brain, leading to an exacerbation of the 
microglial responses observed in this study.
Conclusion
This is the first report of effects of SiNPs on 
primary microglia. The main effect observed 
is increased production of intra  cellular ROS 
and RNS, altered TNF‑α and COX‑2 gene 
expression, and a small but detectable release 
of IL-1β. Other studies have suggested that 
microglia can internalize SiNPs and be used 
as a vehicle for gene therapy and as a con-
trast agent for glioma treatment (Kircher et al. 
2003; Ribot et al. 2007; Voisin et al. 2007). 
Although this approach may advance the 
field of nano  medicine, little is known about 
the possible adverse effects of SiNPs once 
they have been internalized by microglia in 
the brain parenchyma. Our study suggests 
that at concentrations as low as 4 NPs/µL 
(7.28 × 10–4 µg/mL), there is a significant 
increase of ROS and RNS. Because NPs 
may gain entry into the brain via multiple 
pathways, it is possible that microglia may 
be affected in both supra  tentorial and infra-
tentorial regions of the brain. This could cause 
deleterious effects, because the continuous 
production of ROS by microglia is capable of 
damaging neurons in their vicinity. Moreover, 
SiNP-induced microglial dysfunction can lead 
to their inability to maintain neuronal health.
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